Deutsche Bank’s Prelude Therapeutics PRLD Stock Holding History

Deutsche Bank’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-80,723	Closed	-$62.2K	–	3704
2025 Q1	$62.2K	Sell	80,723 -43,176	-35%	-$40.3K	﹤0.01%	3335
2024 Q4	$159K	Buy	123,899 +109,281	+748%	+$145K	﹤0.01%	3162
2024 Q3	$30.3K	Hold	14,618	–	–	﹤0.01%	3431
2024 Q2	$55.7K	Buy	+14,618	New	+$59.5K	﹤0.01%	3302
2023 Q4	–	Sell	-446	Closed	-$1.38K	–	3684
2023 Q3	$1.38K	Buy	+446	New	+$1.67K	﹤0.01%	3652
2022 Q2	–	Sell	-6,187	Closed	-$43K	–	4279
2022 Q1	$43K	Sell	6,187 -700	-10%	-$6.4K	﹤0.01%	3883
2021 Q4	$86K	Buy	6,887 +350	+5%	+$5.69K	﹤0.01%	3766
2021 Q3	$205K	Sell	6,537 -30,596	-82%	-$991K	﹤0.01%	3556
2021 Q2	$1.06M	Buy	37,133 +547	+1%	+$19.5K	﹤0.01%	2730
2021 Q1	$1.58M	Buy	36,586 +29,836	+442%	+$1.98M	﹤0.01%	2350
2020 Q4	$483K	Buy	+6,750	New	+$336K	﹤0.01%	2929

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Deutsche Bank's PRLD Position: Q2 2025 in Review

Deutsche Bank sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 80,723 shares — an estimated $62.2K sold.

Deutsche Bank first reported a position in PRLD in Q4 2020 and held it in 11 quarters. The position peaked at $1.58M in Q1 2021. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

Deutsche Bank reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
Deutsche Bank sold 80,723 Prelude Therapeutics shares in Q2 2025, an estimated $62.2K.
Deutsche Bank first reported a position in Prelude Therapeutics in Q4 2020 and held it in 11 quarters.
Deutsche Bank's Prelude Therapeutics position peaked at $1.58M in Q1 2021.
50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.